6533b857fe1ef96bd12b514e

RESEARCH PRODUCT

The broad phenotypic spectrum of PPP2R1A -related neurodevelopmental disorders correlates with the degree of biochemical dysfunction

Amy MctagueAmy MctagueSiddharth SrivastavaTamison JewettAli Al-beshriConstance Smith-hicksShelagh JossJennifer A. SullivanSarju G. MehtaKoenraad DevriendtPascal JosetLaurence FaivreEmma KivuvaWilliam G. WilsonGunnar HougeNaama OrensteinYana HoorneVickie L. HannigMalou HeijligersBart LoeysVandana ShashiKatrina PrescottIris VerbinnenAnnick ToutainLauren M. BaldwinStephen P. FultonKatharina SteindlAnne Marie ChildsAnna ChasseventShelley TownerCornelia Daumer-haasOded WechsbergAlison MaleAlison MaleHannah F. JohnsonWendy K. ChungAnita RauchAnna RuizIsabelle MaystadtSara ReynhoutSara ReynhoutSébastien MouttonYvette Van IerlandVeerle JanssensVeerle JanssensFrédéric LaumonnierMartina BaethmannLisa LenaertsVani JainVinod VargheseSuzanne M. KoudijsElisabeth GabauBonnet-brilhault FrédériqueRizwan HamidSusan E. HolderBarbara Plecko

subject

0301 basic medicineMicrocephaly[SDV]Life Sciences [q-bio]Intellectual disability030105 genetics & heredityBioinformaticsEpilepsyNeurodevelopmental disorderIntellectual disabilityCOREProtein Phosphatase 2SPECIFICITYGenetics (clinical)PROTEIN PHOSPHATASE 2APhenotypeHypotoniaFAMILY3. Good healthPP2A[SDV] Life Sciences [q-bio]PPP2R1APPP2R5DINSIGHTSintellectual disabilityMicrocephalyMuscle Hypotoniamedicine.symptomLanguage delay[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human geneticsArticle03 medical and health sciencesNeurodevelopmental disorder[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyEpilepsybusiness.industryMacrocephalyDEPHOSPHORYLATIONmedicine.diseaseneurodevelopmental disorder030104 developmental biology[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsNeurodevelopmental DisordersSUBUNITepilepsyHuman medicineTAUbusinessTranscription Factors

description

PURPOSE: Neurodevelopmental disorders (NDD) caused by protein phosphatase 2A (PP2A) dysfunction have mainly been associated with de novo variants in PPP2R5D and PPP2CA, and more rarely in PPP2R1A. Here, we aimed to better understand the latter by characterizing 30 individuals with de novo and often recurrent variants in this PP2A scaffolding Aα subunit. METHODS: Most cases were identified through routine clinical diagnostics. Variants were biochemically characterized for phosphatase activity and interaction with other PP2A subunits. RESULTS: We describe 30 individuals with 16 different variants in PPP2R1A, 21 of whom had variants not previously reported. The severity of developmental delay ranged from mild learning problems to severe intellectual disability (ID) with or without epilepsy. Common features were language delay, hypotonia, and hypermobile joints. Macrocephaly was only seen in individuals without B55α subunit-binding deficit, and these patients had less severe ID and no seizures. Biochemically more disruptive variants with impaired B55α but increased striatin binding were associated with profound ID, epilepsy, corpus callosum hypoplasia, and sometimes microcephaly. CONCLUSION: We significantly expand the phenotypic spectrum of PPP2R1A-related NDD, revealing a broader clinical presentation of the patients and that the functional consequences of the variants are more diverse than previously reported. ispartof: Genetics In Medicine vol:23 issue:2 ispartof: location:United States status: Published online

10.1038/s41436-020-00981-2https://ddd.uab.cat/record/238621